| Sumario: | The article focuses on a novel variant of the phosphatase interacting protein 1 (PSTPIP1) gene, specifically the H234Q variant, which expands the understanding of PSTPIP1-associated disorders and suggests the potential efficacy of JAK inhibitor therapy. The case study details a 42-year-old Canadian patient with atypical symptoms of PSTPIP1-associated autoinflammatory disease, including recurrent fever, arthralgia, and granuloma annulare, linked to the H234Q variant. Genetic analysis indicated that this variant enhances inflammasome activation, leading to increased IL-1β secretion and pyroptosis. The patient's treatment with the JAK inhibitor tofacitinib resulted in significant clinical improvement, highlighting a promising therapeutic avenue for managing these complex disorders.
|
|---|